US20150038533A1 - Phacetoperane for the treatment of attention-deficit hyperactivity disorder - Google Patents

Phacetoperane for the treatment of attention-deficit hyperactivity disorder Download PDF

Info

Publication number
US20150038533A1
US20150038533A1 US14/360,355 US201214360355A US2015038533A1 US 20150038533 A1 US20150038533 A1 US 20150038533A1 US 201214360355 A US201214360355 A US 201214360355A US 2015038533 A1 US2015038533 A1 US 2015038533A1
Authority
US
United States
Prior art keywords
phenyl
piperidin
alpha
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/360,355
Other languages
English (en)
Inventor
Eric Konofal
Bruno Figadere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NLS Pharma AG
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of US20150038533A1 publication Critical patent/US20150038533A1/en
Assigned to ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS reassignment ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FIGADERE, BRUNO, KONOFAL, ERIC
Assigned to NLS-1 PHARMA AG reassignment NLS-1 PHARMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Assigned to NLS PHARMA AG reassignment NLS PHARMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NLS-1 PHARMA AG
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention relates to the treatment of attention deficit hyperactivity disorder.
  • ADHD Attention deficit hyperactivity disorder
  • DSM-IV TR Diagnostic and Statistical Manual of Mental Disorders
  • This disorder is a frequent reason for consultation in child psychopathology. According to studies, its prevalence in the general child population is from 2 to 5%. The signs of inattentiveness may persist beyond childhood and are responsible for social, relational and affective difficulties. Up to 60% of children with ADHD continue to present characteristic symptoms at adult age, although the typical presentation corresponds to completely different criteria (work, relationships, parenthood, etc.). Studies have shown that the disorder is clinically significant at adult age, with dysfunction in professional, familial and affective respects. Moreover, comorbidity is high, and can complicate diagnosis and treatment.
  • Ritalin® (methylphenidate hydrochloride) is currently the drug most prescribed for treating ADHD, but it is not free from side-effects, which can be severe.
  • the invention relates to alpha-phenyl(piperidin-2-yl)methanol, or a pharmaceutically acceptable salt or ester thereof, for use in the treatment of ADHD.
  • the acetate of alpha-phenyl(piperidin-2-yl)methanol in the threo form is used, or a pharmaceutically acceptable salt thereof.
  • said phacetoperane is in its dextrorotatory form.
  • said phacetoperane is in its laevorotatory form.
  • the invention provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.
  • FIG. 1 is a schematic diagram of the T-maze test: c0, c1 and c2 are the limits of the guillotine doors.
  • FIG. 2 presents a bar-chart comparison of a behavioural test on the juvenile rat, submitted to the T-maze test, a model of ADHD. It shows the results in the “pre-medication” phase (left columns), “medication” phase (middle columns), and “post-medication” phase (right columns).
  • the number of times the rat chooses the reward that is large but is deferred by 30 s is an indicator of the level of impulsiveness (the higher the number of choices, the less the animal is regarded as impulsive). Phacetoperane is compared with methylphenidate.
  • treatment signifies therapeutic or prophylactic treatment of ADHD or of one of its symptoms, in particular lack of attention, hyperactivity, or impulsiveness. This term includes improvement of the symptoms of the disease.
  • the “patient” with ADHD is a human: child, adolescent or adult. More particularly, the patient is a subject of normal intelligence, evaluated by an Intelligence Quotient test above 80 (by an evaluation of intelligence, such as WISC-IV, for example). Therefore the subject does not present any mental impairment or delayed development, including behavioural or motor disorders connected with delayed mental development (backwardness), such as oligophrenia or hyperkinesia of neurological origin.
  • an “erythro diastereoisomer” of a compound having two asymmetric carbons includes the (R,S) enantiomer and the (S,R) enantiomer of said compound as well as the racemic mixtures thereof.
  • a “threo diastereoisomer” of a compound having two asymmetric carbons includes the (R,R) enantiomer and the (S,S) enantiomer of said compound as well as the racemic mixtures thereof.
  • alpha-phenyl-2-piperidinemethanol or phenyl(piperidin-2-yl)methanol, or else alpha-phenyl(piperidin-2-yl)methanol.
  • Phhacetoperane means the threo diastereoisomer of alpha-phenyl-2-piperidinemethanol acetate.
  • Alpha-phenyl-2-piperidinemethanol acetate is also called hereinafter phenyl(piperidyn-2-yl)methyl acetate or alpha-phenyl(piperidyn-2-yl)methyl acetate and is represented by formula (B).
  • levophacetoperane means the laevorotatory enantiomer of phacetoperane, i.e. the (R,R) enantiomer.
  • dextrophacetoperane means the dextrorotatory enantiomer of phacetoperane, i.e. the (S,S) enantiomer.
  • the compounds for use in the invention are alpha-phenyl(piperidin-2-yl)methanol of formula (A), or the pharmaceutically acceptable salts and esters thereof, alone or mixed.
  • ester in the form of acetate is preferred.
  • Alpha-phenyl-2-piperidinemethanol acetate of formula (B) was synthesized in the 1950s under code 7890RP, by the Research Laboratories of the company Rhone Poulenc (cf. U.S. Pat. No. 2,928,835).
  • the present invention relates to the various threo and erythro diastereoisomers of alpha-phenyl(piperidin-2-yl)methanol, the pharmaceutically acceptable salts and esters thereof, whether in racemic form or in enantiomeric form.
  • the present invention relates to the threo diastereoisomers of these compounds.
  • the present invention relates to the threo diastereoisomer of alpha-phenyl(piperidin-2-yl)methyl acetate, or a pharmaceutically acceptable salt thereof, for use in the treatment of an attention deficit hyperactivity disorder (ADHD).
  • ADHD attention deficit hyperactivity disorder
  • the threo diastereoisomer of alpha-phenyl(piperidin-2-yl)methyl acetate, or a pharmaceutically acceptable salt thereof is used in racemic form, i.e. in the form of a mixture of its (S,S) and (R,R) enantiomers.
  • the laevorotatory form of alpha-phenyl(piperidin-2-yl)methyl threo-acetate or a pharmaceutically acceptable salt thereof is used.
  • the laevorotatory form corresponds to the (R,R) enantiomer.
  • This form initially coded 8228RP, was then denoted by levophacetoperane (formula I).
  • the dextrorotatory form of alpha-phenyl(piperidin-2-yl)methyl threo-acetate is used, i.e. the (S,S) enantiomer, which can be designated here as dextrophacetoperane of formula (II).
  • the applicant is of the opinion that the use of the dextrorotatory enantiomer of phacetoperane or of a racemic mixture enriched in the dextrorotatory enantiomer of phacetoperane is advantageous when we wish to treat ADHD without causing a sedative effect in the patient.
  • a racemic mixture of phacetoperane enriched in the dextrorotatory enantiomer means a mixture for which the molar percentage of dextrorotatory enantiomer (i.e. (S,S)) is above 50%, preferably above 70% and even more preferably above 90%, the molar percentage of dextrorotatory enantiomer being calculated relative to the total number of moles of phacetoperane in said mixture.
  • a molar percentage of dextrorotatory enantiomer above 90% includes a percentage of dextrorotatory enantiomer above 92%, above 93%, above 94%, above 95%, above 96%, above 97%, above 98%.
  • dextrophacetoperane is used in the context of the invention, more preferably in the form of a salt, for example a hydrochloride.
  • the compounds of the invention can be produced by any method known by a person skilled in the art.
  • a person skilled in the art will be able in particular to refer to patent U.S. Pat. No. 2,928,835, which describes the production of phacetoperane in racemic form and in laevorotatory form.
  • phacetoperane, or a salt thereof, in racemic form or in the form of (S,S) or (R,R) enantiomer can be obtained from alpha-phenyl-(piperidin-2-yl)-methanol in the threo form.
  • Threo-alpha-phenyl-(piperidin-2-yl)-methanol can be obtained according to the following reaction scheme:
  • This reaction scheme comprises the following steps:
  • Phacetoperane in racemic form can be obtained by acetylation of the diastereoisomer of alpha-phenyl-(piperidin-2-yl)-methanol obtained in step 3.
  • Splitting of phacetoperane or threo-phenyl-(piperidin-2-yl)methanol can be carried out by conventional methods of enantiomeric resolution, for example by chiral stationary phase chromatography or by preferential crystallization using a splitting agent, generally a chiral compound such as tartaric acid, camphorsulphonic acid, dibenzoyltartaric acid or else N-acetyl leucine.
  • a splitting agent generally a chiral compound such as tartaric acid, camphorsulphonic acid, dibenzoyltartaric acid or else N-acetyl leucine.
  • patent U.S. Pat. No. 2,928,835 describes separation of the (S,S) and (R,R) enantiomers of threo-phenyl-(piperidin-2-yl)-methanol by fractional crystallization using ( ⁇ )dibenzoyltartaric acid in propanol.
  • the dextrorotatory enantiomer remains in solution whereas the laevorotatory enantiomer is precipitated in the form of dibenzoyltartrate salt.
  • (+)-dibenzoyltartaric acid would allow selective crystallization of the dextrorotatory enantiomer of phacetoperane.
  • an additional object according to the invention is a method of preparing the compound in the form of (S,S) enantiomer of formula (VI):
  • the alkaline salts of tri-sec-butylborohydride include the lithium, potassium, and sodium salts.
  • the alkaline salt of tri-sec-butylborohydride is lithium tri-sec-butyl borohydride.
  • the protecting group can be any protecting group of the amine function known by a person skilled in the art. In particular, it can be a group that generates steric hindrance. In particular it can be the Boc group (tert-butyloxycarbonyl).
  • R 1 is a Boc group and the alkaline salt of tri-sec-butylborohydride is lithium tri-sec-butylborohydride.
  • the compound of formula (V) corresponds to (S)-phenyl-(piperidin-2-yl)-methanone in protected or unprotected form.
  • (S)-phenyl-(piperidin-2-yl)-methanone can be obtained by any method known by a person skilled in the art.
  • this compound can be obtained advantageously by reaction of a Weinreb amide with a suitable organometallic compound.
  • the method according to the invention comprises the following steps:
  • step (i) of the method is characterized by one, several or all of the following characteristics:
  • step (i) when the compound of formula (VII) is a carboxylic acid (Y ⁇ OH), the reaction between said carboxylic acid and the N,O-dialkylhydroxylamine can be carried out using one or more peptide coupling agents such as the carbodiimides and the phosphonium salts.
  • peptide coupling agents such as the carbodiimides and the phosphonium salts.
  • each step of the method according to the invention can be carried out in the presence of a solvent and, optionally, in the presence of a base or an acid.
  • the method of preparing the compound of formula (VI) in the form of (S,S) enantiomer can be used advantageously in the preparation of alpha-phenyl(piperidin-2-yl)methanol acetate in the form of (S,S) enantiomer.
  • an additional object of the invention is a method of preparing the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol acetate(dextrophacetoperane) or a pharmaceutically acceptable salt thereof, said method comprising the following steps
  • the method of preparing the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methyl acetate(dextrophacetoperane) or a pharmaceutically acceptable salt thereof according to the invention comprises the following steps:
  • the acetylation step can be carried out by methods well known by a person skilled in the art, in particular by reacting the alcohol of formula (VI) with acetic anhydride or ethanoyl chloride.
  • R 1 is a Boc group
  • the step of deprotection of the piperidine group can be carried out by acid hydrolysis for example in the presence of hydrochloric acid or trifluoroacetic acid.
  • the method according to the invention comprises the following steps:
  • each step of the method according to the invention can be carried out in the presence of a solvent and, optionally, in the presence of a base or an acid.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound described above, alone or mixed, and a pharmaceutically acceptable vehicle.
  • compositions according to the invention can be administered in various ways and in various forms.
  • they can be administered systemically, by the oral route, by inhalation or by injection, for example by the intravenous, intramuscular, subcutaneous, transdermal, intraarterial route, etc., the intravenous, intramuscular, subcutaneous, and oral routes and by inhalation being preferred.
  • the compounds are generally packaged in the form of liquid suspensions, which can be injected by means of syringes or by infusion, for example.
  • the compounds are generally dissolved in saline, physiological, isotonic, buffered, solutions etc., compatible with pharmaceutical use and known by a person skilled in the art.
  • compositions can contain one or more agents or vehicles selected from dispersants, solubilizers, stabilizers, preservatives, etc.
  • Agents or vehicles usable in liquid and/or injectable formulations are notably methylcellulose, hydroxymethylcellulose, carboxymethylcellulose, polysorbate 80, mannitol, gelatin, lactose, vegetable oils, acacia , etc.
  • the compounds can also be administered in the form of gels, oils, tablets, suppositories, powders, hard capsules, soft capsules, aerosols, etc., optionally by means of pharmaceutical forms or devices ensuring prolonged and/or delayed release.
  • an agent such as cellulose, carbonates or starches is used advantageously.
  • the compound is used in a form suitable for administration by the oral route.
  • Preferably it can be in a form suitable for prolonged release.
  • it can moreover be in the form of a combination or of a mixture of microgranules for immediate release, and of microgranules for prolonged release.
  • the invention relates to the treatment of a disorder of attention, more particularly of attention deficit hyperactivity disorder (ADHD), with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane.
  • ADHD attention deficit hyperactivity disorder
  • alpha-phenyl(piperidin-2-yl)methanol or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane.
  • the compound can be administered in monotherapy or in combination with one or more other active principles, including psychostimulants (such as methylphenidate or amphetamine).
  • psychostimulants such as methylphenidate or amphetamine.
  • the compounds of the invention can be useful for treating, in any subject (adult or child), sleep disorders or disorders of maintaining wakefulness (narcolepsy, hypersomnia), mood disorders, behavioural disorders (agitation, instability), oppositional disorder (with or without provocation), anxiety disorders, personality disorders (pervasive developmental disorder, borderline states, schizophrenia), Alzheimer's disease, old-age dementias (fronto-temporal dementia, cortico-basal dementia, Lewy body disease), Parkinson's disease, Gilles de la Tourette syndrome, essential tremor, and restless legs syndrome (RLS).
  • ADHD attention deficit hyperactivity disorder
  • daily doses of about 5 to 1000 mg, preferably about 5 to 500 mg, more preferably 5 to 100 mg, more preferably about 5 to 30 mg, 5 to 20 mg, or 5 to 10 mg, are preferred. Divided doses are preferably administered to the patient.
  • Dextrophacetoperane hydrochloride was obtained according to the following synthesis scheme in the form of a white powder in a total yield from 20% to 25% and with a purity above 97%.
  • the acid (1) (0.5 g, 2.13 ⁇ 10 ⁇ 3 mol) is dissolved in CH 2 Cl 2 .
  • N—O-dimethylhydroxylamine hydrochloride (0.254 g, 2.55 ⁇ 10 ⁇ 3 mol) and triethylamine (7.51 ⁇ 10 ⁇ 3 mol) are added to this solution.
  • Benzotriazol-1-yl-oxy-tris(dimethylamino)-phosphonium hexafluorophosphate (BOP) (1.06 g, 2.343 ⁇ 10 ⁇ 3 mol) is then added, and the reaction mixture is stirred for 6 h.
  • the reaction mixture is then diluted in CH 2 Cl 2 and transferred to a dropping funnel containing 1M HCl.
  • the hydroxamate (2) (0.470 g, 1.72 ⁇ 10 ⁇ 3 mol) is dissolved in ethyl ether, put under a nitrogen atmosphere and cooled to ⁇ 23° C. Phenyllithium (1.8M in dibutyl ether, 0.955 mL, 1.72 ⁇ 10 ⁇ 3 mol) is then added. After stirring for 3 h, the reaction mixture is added to a 1M solution of KH 2 PO 4 with crushed ice. The aqueous phase is extracted with ethyl acetate, dried, filtered and evaporated. The oil obtained is purified by flash chromatography (cyclohexane/ethyl acetate 8:2) to give the ketone (3) (0.253 g, 52%).
  • the ketone (3) (0.365 g, 1.26 ⁇ 10 ⁇ 3 mol), in anhydrous THF and under a nitrogen atmosphere, is cooled to ⁇ 78° C.
  • L-Selectride (1M in THF, 3.79 mL, 3.78 ⁇ 10 ⁇ 3 mol) is then added.
  • water and then 35% hydrogen peroxide are added to the reaction mixture, which is then stirred for 2 h.
  • the solution obtained is then diluted in water and ethyl acetate, and the aqueous phase is extracted with ethyl acetate.
  • the combined organic phases are washed with water, then with saturated NaCl, dried over Na 2 SO 4 , then filtered and finally evaporated.
  • the oil obtained is purified by flash chromatography (cyclohexane/ethyl acetate 8:2) to give the alcohol (4) (0.277 g, 76%).
  • the alcohol (4) (0.265 g, 0.91 ⁇ 10 ⁇ 3 mol), triethylamine (0.378 mL, 2.73 ⁇ 10 ⁇ 3 mol), 4-DMAP (5.55 mg, 4.55 ⁇ 10 ⁇ 5 mol) and acetic anhydride (0.516 mL, 5.46 ⁇ 10 ⁇ 3 mol) are stirred at room temperature for 14 h.
  • the solution is then basified with 10% K 2 CO 3 and extracted with ethyl ether.
  • the combined organic phases are dried over Na 2 SO 4 , then filtered and evaporated.
  • the product obtained is purified by flash chromatography (cyclohexane/ethyl acetate 8:2) to give the acetate (5) (0.291 g, 95%).
  • the acetate (5) (5.7 mg, 1.71 ⁇ 10 ⁇ 5 mol) is dissolved in ethyl ether, and 12N hydrochloric acid (0.02 mL) is then added. After stirring for 15 minutes, the solution is evaporated and dried using a vane pump to give dextrophacetoperane (4 mg, 87%) in the form of a white powder.
  • the T-maze behavioural test makes it possible to measure the ability to wait that is displayed by a juvenile animal (here, the rat) when it is given a choice between a quick and immediate food reward or a large but deferred reward.
  • This test allows assessment of the ability to wait, i.e. the level of impulsiveness.
  • methylphenidate (Ritalin®) seems to increase the number of times the large but deferred reward is chosen.
  • amphetamine an amphetamine-type stimulant
  • noradrenaline reuptake inhibitors atomoxetine, mazindol
  • eugregoric agents modafinil, lauflumide
  • the T-maze test in juvenile animals, is appropriate for testing for improvement in control of impulsiveness by drugs for treating ADHD.
  • IP intraperitoneally
  • Protocol The experiments were carried out between 8 h and 18 h at room temperature (22 ⁇ 1.5° C.) under artificial lighting in calm conditions.
  • 1st phase accustoming.
  • the animals are first submitted to two to six sessions of 5 min of accustoming.
  • the rat is gently placed in the start area, which is then closed with a guillotine door inserted in the slit.
  • the animal is allowed to explore the device freely and eat rewards placed in dishes.
  • 2nd phase pre-training.
  • the rat After a door has been placed in slit c2 near each goal box, the rat is placed in the start area. When it enters one of the two arms, a door is inserted behind it in slit c1 near the choice area and the door placed in slit c2 is removed. Once the animal enters the goal box, the door is replaced in slit c2. The rat is recovered from the goal box once it has eaten the pellets. The animal is then put back in its cage for 2 to 3 min. Each rat is submitted one to three times per day to five test sessions. In 4 to 12 sessions, the rat selects the arm giving access to the large reward in more than 80% of the tests. Training then begins.
  • 3rd phase training.
  • the rats follow 1 to 4 times/day training sessions of 5 tests during which a delay is introduced before access to the large reward.
  • the rat is placed in the start area.
  • a second door is inserted behind it in slit c1 near the choice area, so that the rat choosing the arm leading to the large reward can be detained in this arm for 30 s—the waiting delay—before gaining access to the reinforcement. Otherwise, if the animal chooses the arm leading to the small reward, the door placed in slit c2 is opened immediately, allowing the animal to enter the goal box.
  • Drug testing begins when the animal chooses the large reward delayed by 30 s in 2 tests out of 5 (or less) during two consecutive sessions and in 1 test out of 5 (or less) in the next session. The animals that do not meet this criterion for 12 sessions are eliminated from the experiment.
  • Medication sessions 1 and 2 are carried out for one and two days, respectively, after the sessions of pre-medication control.
  • the two sessions of post-medication control are carried out for one day after medication session 2.
  • BLK-10, methylphenidate or placebo are administered before each medication session.
  • Methylphenidate, used as reference product, and BLK-010 are administered before the test. These two molecules improve the ability to wait in young Wistar rats submitted to the T-maze test relative to the control.
  • the compound BLK-010 appears significantly and statistically more effective than methylphenidate in the ability to wait in young Wistar rats submitted to the T-maze test.
  • Phacetoperane (1 mg/kg) does not lead to any habituation, nor even expenditure (before and after treatment). It is robust over time (during the different tests) and is always found to be more effective than methylphenidate (3 mg/kg).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US14/360,355 2011-11-29 2012-11-29 Phacetoperane for the treatment of attention-deficit hyperactivity disorder Abandoned US20150038533A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1160902A FR2983197B1 (fr) 2011-11-29 2011-11-29 Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
FR1160902 2011-11-29
PCT/FR2012/052749 WO2013079873A1 (fr) 2011-11-29 2012-11-29 Phacetoperane pour traiter un trouble deficit de l'attention hyperactivite

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2012/052749 A-371-Of-International WO2013079873A1 (fr) 2011-11-29 2012-11-29 Phacetoperane pour traiter un trouble deficit de l'attention hyperactivite

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/913,481 Continuation US10456387B2 (en) 2011-11-29 2018-03-06 Phacetoperane for treating of attention deficit hyperactivity disorder

Publications (1)

Publication Number Publication Date
US20150038533A1 true US20150038533A1 (en) 2015-02-05

Family

ID=47436090

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/360,355 Abandoned US20150038533A1 (en) 2011-11-29 2012-11-29 Phacetoperane for the treatment of attention-deficit hyperactivity disorder
US15/913,481 Expired - Fee Related US10456387B2 (en) 2011-11-29 2018-03-06 Phacetoperane for treating of attention deficit hyperactivity disorder
US16/573,493 Abandoned US20200061044A1 (en) 2011-11-29 2019-09-17 Phacetoperane for treating of attention deficit hyperactivity disorder
US17/521,010 Abandoned US20220054471A1 (en) 2011-11-29 2021-11-08 Phacetoperane for treating of attention deficit hyperactivity disorder

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/913,481 Expired - Fee Related US10456387B2 (en) 2011-11-29 2018-03-06 Phacetoperane for treating of attention deficit hyperactivity disorder
US16/573,493 Abandoned US20200061044A1 (en) 2011-11-29 2019-09-17 Phacetoperane for treating of attention deficit hyperactivity disorder
US17/521,010 Abandoned US20220054471A1 (en) 2011-11-29 2021-11-08 Phacetoperane for treating of attention deficit hyperactivity disorder

Country Status (19)

Country Link
US (4) US20150038533A1 (de)
EP (2) EP2785344B1 (de)
JP (2) JP6143112B2 (de)
CN (1) CN104363909B (de)
CA (1) CA2856701C (de)
CY (1) CY1118537T1 (de)
DK (1) DK2785344T3 (de)
ES (2) ES2792875T3 (de)
FR (1) FR2983197B1 (de)
HR (1) HRP20161776T1 (de)
HU (1) HUE030575T2 (de)
IL (1) IL232897B (de)
LT (1) LT2785344T (de)
PL (1) PL2785344T3 (de)
PT (1) PT2785344T (de)
RS (1) RS55523B1 (de)
SI (1) SI2785344T1 (de)
SM (1) SMT201600466B (de)
WO (1) WO2013079873A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928835A (en) * 1959-02-19 1960-03-15 Rhone Poulenc Sa New esters
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2838739B1 (fr) * 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
FR2842804B1 (fr) * 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928835A (en) * 1959-02-19 1960-03-15 Rhone Poulenc Sa New esters
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bluelight, http://www.bluelight.org/vb/threads/362377-Ethyl-Ester-Analogues-of-DARIs, publicly available on 10/02/20008. *
Opiophile, http://forum.opiophile.org/showthread.php?25721-Stimulants-that-would-make-good-meds&s=dd38ea19d8268cf2c55cec25dc46a107, publicly available on 08/24/2009 . *
Rosler et al, World J Biol. Psychiatry. 2010 Aug; 11(5):709-18. *
Wen et al, Oral Controlled Release Formulation Design and Drug Delivery, Copyrighted (@) 2010. *

Also Published As

Publication number Publication date
US20200061044A1 (en) 2020-02-27
PT2785344T (pt) 2017-01-18
ES2792875T3 (es) 2020-11-12
SMT201600466B (it) 2017-03-08
JP6143112B2 (ja) 2017-06-07
IL232897B (en) 2019-02-28
LT2785344T (lt) 2017-04-25
EP3153168B1 (de) 2020-02-26
CA2856701C (fr) 2020-07-28
EP3153168A1 (de) 2017-04-12
CN104363909B (zh) 2017-12-15
CN104363909A (zh) 2015-02-18
DK2785344T3 (en) 2017-01-23
JP2014533742A (ja) 2014-12-15
RS55523B1 (sr) 2017-05-31
US20220054471A1 (en) 2022-02-24
FR2983197B1 (fr) 2014-07-25
IL232897A0 (en) 2014-07-31
FR2983197A1 (fr) 2013-05-31
ES2610563T3 (es) 2017-04-28
CA2856701A1 (fr) 2013-06-06
EP2785344A1 (de) 2014-10-08
SI2785344T1 (sl) 2017-04-26
JP2017149763A (ja) 2017-08-31
CY1118537T1 (el) 2017-07-12
HUE030575T2 (en) 2017-05-29
HRP20161776T1 (hr) 2017-03-10
US10456387B2 (en) 2019-10-29
WO2013079873A1 (fr) 2013-06-06
EP2785344B1 (de) 2016-11-02
PL2785344T3 (pl) 2017-06-30
US20180214436A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
JP5836280B2 (ja) 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
ES2329739T3 (es) Analogos de cocaina.
US9624164B2 (en) Phenyl carbamate compounds for use in preventing or treating epilepsy
CA2822453C (en) Novel morphinans useful as analgesics
KR20220131520A (ko) 아릴시클로헥실아민 유도체 및 정신장애 치료에서의 이의 용도
AU2016200765A1 (en) Methods for treating fibromyalgia syndrome
ES2609264T3 (es) Formas sólidas que comprenden (-)-O-desmetilvenlafaxina y usos de las mismas
CA2922340A1 (en) Ketamine derivatives
ES2711619T3 (es) Compuesto carbamato de fenilo y relajante muscular que contiene dicho compuesto
ES2283122T3 (es) Procedimientos y composiciones para el tratamiento de la depresion.
US6835754B2 (en) Use of aryl nitrone compounds in methods for treating neuropathic pain
US20220054471A1 (en) Phacetoperane for treating of attention deficit hyperactivity disorder
US11352365B2 (en) Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
WO2015046405A1 (ja) 鎮痛剤
US11578092B2 (en) Compound for preventing or treating neurodegenerative disease and application thereof
ES2256499T3 (es) Dimetil(1-(1-fenilciclohexil)piperidin-3-imetil) aminas sustituidas y su utilizacion como analgesicos.
WO2024039599A1 (en) Phenethylamines and cathinones precursors
JP2023528644A (ja) 長時間作用性の低嗜癖性ｈｎｋ誘導体及びその製造方法
JPH03223251A (ja) アミノナフタレン化合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KONOFAL, ERIC;FIGADERE, BRUNO;SIGNING DATES FROM 20160421 TO 20160502;REEL/FRAME:038683/0471

AS Assignment

Owner name: NLS-1 PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS;REEL/FRAME:039217/0155

Effective date: 20160126

AS Assignment

Owner name: NLS PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NLS-1 PHARMA AG;REEL/FRAME:041592/0419

Effective date: 20160910

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION